Table 3 Overall antimicrobial susceptibility and trends for 2014, 2016 and 2018
Antimicrobials | 2014 n (%) | 2016 n (%) | 2018 n (%) | Total study period - n (%) | Episodes omitteda (n) |
|---|---|---|---|---|---|
Gram positive organisms | |||||
 Staphylococcus aureus | |||||
  Cloxacillin | 0/4 (0.0) | 4/10 (40.0) | 1/10 (10.0) | 5/24 (20.8) | 0 |
  Vancomycin | 3/3 (100.0) | 10/10 (100.0) | 9/9 (100.0) | 22/22 (100.0) | 2 |
 CoNS | |||||
  Cloxacillin | 5/100 (4.5) | 13/114 (10.4) | 14/139 (11.1) | 32/363 (8.8) | 0 |
  Vancomycin | 11/11 (100.0) | 14/14 (100.0) | 21/21 (100.0) | 46/46 (100.0) | 317 |
 Enterococcus species | |||||
  Ampicillin | 6/18 (33.3) | 7/17 (41.2) | 11/29 (37.9) | 24/64 (37.5) | 0 |
  Vancomycin | 18/18 (100.0) | 17/17 (100.0) | 29/29 (100.0) | 64/64 (100) | 0 |
Gram negatives organisms | |||||
 Enterobacterales | |||||
  Amikacin | 37/41 (90.2) | 30/43 (38.6) | 27/33 (57.6) | 94/117 (80.3) | 1 |
  Cefotaxime | 10/41 (24.4) | 13/43 (30.2) | 17/33 (51.5) | 40/117 (34.2) | 1 |
  Ceftazidime | 10/40 (25.0) | 13/43 (30.2) | 18/33 (54.5) | 41/116 (35.3) | 2 |
  Ciprofloxacin | 22/41 (53.7) | 31/44 (70.5) | 20/32 (62.5) | 73/117 (62.4) | 1 |
  Ertapenem | 33/34 (97.1) | 34/38 (89.5) | 26/31 (83.9) | 93/103 (90.3) | 15 |
  Gentamicin | 10/39 (25.6) | 17/44 (38.6) | 19/33 (57.6) | 46/116 (39.7) | 2 |
 Imipenem | 34/34 (100.0) | 39/43 (90.7) | 28/33 (84.8) | 101/110 (91.8) | 8 |
  Meropenem | 40/41 (97.6) | 39/43 (90.7) | 28/33 (84.8) | 108/11792.3 | 1 |
  Piperacillin-Tazobactam | 23/41 (56.1) | 21/39 (53.8) | 17/30 (56.7) | 61/11055.5 | 8 |
 Gram-negative non-fermenters | |||||
  Amikacin | 16/21 (76.2) | 9/17 (52.9) | 1/15 (6.7) | 26/53 (49.1) | 11 |
  Ceftazidime | 1/21 (4.8) | 7/21 (33.3) | 1/16 (6.3) | 9/59 (15.3) | 6 |
  Ciprofloxacin | 5/22 (22.7) | 6/22 (27.3) | 1/17 (5.9) | 12/61 (19.7) | 3 |
  Gentamicin | 2/22 (9.1) | 3/17 (17.6) | 1/13 (7.7) | 6/52 (11.5) | 12 |
  Imipenem | 2/16 (12.5) | 5/20 (25) | 0/16 (0.0) | 7/52 (13.5) | 12 |
  Meropenem | 5/22 (27.2) | 5/20 (25.0) | 0/16 (0.0) | 10/58 (17.2) | 6 |
  Piperacillin-Tazobactam | 4/22 (18.2) | 4/20 (20.0) | 1/16 (6.3) | 6/58 (15.5) | 6 |
 Fungal isolates | |||||
  Fluconazole | 2/9 (22.5) | 7/10 (70.0) | 18/12 (54.8) | 17/31 (54.8) | 0 |